Sarcoma News

Milademetan failed to significantly extend PFS among patients with dedifferentiated liposarcoma, according to topline data released by the agent’s manufacturer.

Staffing shortages at radiation oncology clinics are causing treatment delays and increased patient anxiety, according to results of a national survey from American Society for Radiation Oncology.

Adolescent and young adult cancer survivors who received cardiotoxic treatments exhibited a high burden of poor cardiac function, according to study results presented at American Association for Cancer Research Annual Meeting.

The FDA announced several regulatory actions the past few weeks.

The disparate prevalence of cardiovascular risk factors among adult Black and Hispanic survivors of childhood cancer was comparable to the disparities in the American general population, researchers reported.

In a phase 1 trial of mistletoe extract for patients with cancer, researchers at Johns Hopkins Kimmel Cancer Center found the therapy to not only be safe but also potentially beneficial to quality of life.

University of Chicago Medicine Comprehensive Cancer Center has joined the National Comprehensive Cancer Network as its 33rd member institution.

HHS on Monday released the National Cancer Plan, which includes eight goals and strategies to prevent cancer, reduce related mortality and improve the lives of people living with the disease.

FDA granted full approval to pembrolizumab for treatment of certain adults and children with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors as determined through an FDA-approved test.

Intermittent milademetan appeared effective and mitigated dose-limiting hematologic adverse events among patients with advanced solid tumors and lymphomas, according to study results published in Journal of Clinical Oncology.